Loading the session
Loading the session
Loading instrument
$24.43
+0.04%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:30 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +34.2% (SPY −1.6%, XLV +13.5%). 3 months: −19.1% (SPY −0.4%, XLV +15.5%). 1 year: −22.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ENOV, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 gain of 16.9% was 5.6× its average daily move of 3.0% over the past year, and its largest one-day gain in a record that begins 5 Apr 2022.
Daily closes, split-adjusted · as of 4 Nov 2026
The 4 Nov 2026 close of $24.42 was 23.4% above its 50-day average ($19.79) and 6.0% above its 200-day average ($23.05). It has closed above the 200-day for 1 session, since 4 Nov 2026. The 50-day average crossed below the 200-day on 25 Sep 2026, 28 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
11.7M shares were sold short at the 15 Oct 2026 settlement, 20.3% of the 57.7M shares outstanding; covering them would take 8.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
4 Nov 2026 volume of 3.8M shares was 2.6× the average of the 30 sessions before it (1.5M), as the price rose 16.9%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
November 4, 2026
+16.90%September 1, 2026
−16.51%July 6, 2026
+15.11%